🚨 [Buy MORE?!] THIS Growth Stock is STILL overlooked! Full OSACR (OSCR) Stock Analysis
1 extracted signal · 1 resolved · 0 still active
MoneyvestIndependent analyst profile- Source published
- 08 Sept 2026, 04:09 UTC
- Recorded by Tahlil Plus
- 08 Sept 2026, 06:55 UTC
![Video preview for 🚨 [Buy MORE?!] THIS Growth Stock is STILL overlooked! Full OSACR (OSCR) Stock Analysis](https://i.ytimg.com/vi/U-oAv6oGiiE/hqdefault.jpg)
AI-generated source summary
The video analyzes Oscar Health (OSCR), a health insurance technology company. The stock has experienced significant momentum, surging over 100% year-to-date in 2026, supported by strong operational results and a 46% year-over-year increase in membership, reaching 2.96 million members. Oscar Health reported record financial results for the first half of 2026, leading to an upward revision of its full-year outlook. The company operates as a full-stack digital payer within the Affordable Care Act (ACA) marketplace, utilizing its cloud platform to manage claims, virtual care, and member engagement. Core products include ACA Individual/Family Health Plans and Small Group Plans. Key differentiators are integrated telemedicine, custom provider routing, and automated backend operations. The addressable market is substantial, estimated at $1.6 trillion. Expansion is occurring in the ACA marketplace (~$100B TAM) and through ICHRA & Employer Migration (~$500B+ TAM opportunity). The company's proprietary technology allows for operating expenses to decline as a percentage of revenue with subscriber volume growth. Profitability inflection is noted, with projected operating earnings of $500M-$700M for FY2026. Revenue is projected to grow at ~20% YoY, reaching $18.7B-$19.0B in FY2026. The stock shows strong long-term growth potential, with a projected CAGR of 55.86% by FY2030 and a forward P/S multiple of 0.30. Financial analysis indicates a current estimated intrinsic value of $34.56, suggesting the stock is currently undervalued at $32.25.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Moneyvest
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.